Key Points

• In June 2026, federal Dupixent lawsuits were consolidated into a single multidistrict litigation (MDL No. 3180) in the U.S. District Court for the District of New Jersey before Judge Zahid N. Quraishi. 
• An MDL is not a class action. Each person who files keeps their own individual claim while sharing the pretrial process with other plaintiffs. 
• People who used Dupixent and were later diagnosed with Cutaneous T-Cell Lymphoma may still file a claim that can become part of the MDL. 

Why It Matters

For families dealing with a cancer diagnosis, the legal process can feel confusing and out of reach. The creation of a Dupixent MDL changes that. It signals that courts are taking these claims seriously and that the cases are organized for a coordinated path forward. Knowing how the MDL works, and what it does not do, helps patients understand their rights and decide whether to take action. 

Dupixent Users With Lymphoma Can Take Legal Action

In June 2026, the U.S. Judicial Panel on Multidistrict Litigation announced the formation of a nationwide multidistrict litigation, or MDL, to oversee federal claims involving the link between Dupixent and Cutaneous T-Cell Lymphoma (CTCL). 

If you or a loved one used Dupixent and were diagnosed with lymphoma, the formation of a federal MDL is an important development for your potential case. It does not mean you have automatically joined the litigation. You still need to file your own claim to take part. 

The Dupixent lawyers at Hissey, Mulderig & Friend can explain how the MDL affects you and review your situation at no cost. Call us toll-free at 1-866-806-8117 or use the free claims submission form on this page to get started today. 

What Is an MDL?

An MDL is a legal tool used when many people across the country file similar lawsuits against the same defendants over the same product. Instead of having dozens of judges handle the same questions separately, the cases are gathered before one federal judge for the pretrial phase. 

That judge oversees shared steps such as the exchange of evidence, expert testimony, and key legal rulings. This approach saves time, avoids conflicting decisions, and lets plaintiffs pool their resources against well-funded corporate defendants. 

An MDL is different from a class action. In a class action, one group is treated as a single case. In an MDL, each person keeps their own separate lawsuit. Your claim is evaluated on its own facts, including your medical history and the harm you suffered, and any recovery reflects your individual circumstances. 

How the Dupixent MDL Was Created

The Dupixent litigation grew steadily through late 2025 and early 2026. The first lawsuit was filed in October 2025 on behalf of a woman who died from T-cell lymphoma after using the drug. As more patients came forward, attorneys asked the U.S. Judicial Panel on Multidistrict Litigation, known as the JPML, to centralize the cases. 

The JPML is the body that decides whether to create an MDL and where it will be located. The panel heard arguments in late May 2026. On June 4, 2026, it granted the request and created the Dupixent MDL. 

The litigation is officially titled In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180. At the time it was formed, it included 15 lawsuits that had been filed across 12 federal districts. The drug makers named in the cases are Regeneron Pharmaceuticals and Sanofi. 

Why the MDL Was Sent to New Jersey

The location of an MDL often becomes its own dispute, and this case was no exception. The plaintiffs asked for the litigation to be based in the Northern District of Georgia, where several cases were already pending. The drug makers, who agreed that the cases should be combined, argued for a court in New York instead. 

The JPML chose the District of New Jersey before Judge Zahid N. Quraishi. The panel noted that Sanofi has its principal place of business in New Jersey and that Regeneron maintains offices in the state, with its headquarters nearby in New York. That meant many witnesses and much of the evidence would likely be located in or near the district, making it a practical home for a nationwide litigation. 

What the Dupixent MDL Covers

The MDL is focused on claims involving Cutaneous T-Cell Lymphoma, the rare skin cancer most closely linked to Dupixent in published research. The lawsuits allege that the drug makers failed to warn patients and doctors that Dupixent may cause or accelerate this cancer, and in some cases may have masked early symptoms that look like eczema. 

The panel also left the door open for related claims. Lawsuits involving other forms of T-cell lymphoma may be added to the MDL later through a process called conditional transfer. As awareness of the link spreads among the hundreds of thousands of people who have used Dupixent, the number of cases in the MDL is expected to grow. 

What Happens Next in the Litigation

With the MDL in place, the assigned judge will guide the cases through pretrial proceedings. This usually includes the exchange of documents and testimony, the review of scientific evidence, and decisions on important legal questions that apply to all of the cases. 

In many MDLs, a small group of representative cases, called bellwether trials, are eventually selected to go before a jury. These early trials help both sides understand how juries view the evidence and can encourage settlement discussions. No bellwether trials have been scheduled in the Dupixent litigation yet, since it is still in its early stages. Acting now allows your attorney to prepare your claim as the litigation moves forward. 

What the MDL Means for Your Case

The most important thing to understand is that the MDL does not file your case for you. To be part of the litigation, you must bring your own lawsuit. An attorney can file your claim and, when appropriate, have it transferred into the MDL so it benefits from the coordinated process. 

Filing early in a litigation like this can be an advantage. It gives your lawyer time to gather medical records, preserve evidence, and meet the deadlines that apply to your claim. Because these time limits vary and can be strict, it is best not to wait to learn your options. 

Contact a Lawyer to Find Out If You Qualify

If you or a loved one was diagnosed with Cutaneous T-Cell Lymphoma after using Dupixent, you may be eligible to join the federal MDL or file an individual lawsuit and receive compensation.  

The attorneys at Hissey, Mulderig & Friend are currently investigating claims involving Dupixent users who were diagnosed with CTCL. There is no cost to speak with a lawyer and find out if you qualify, and you will only have to pay legal fees if we recover compensation in your case.  

Talk with a lawyer about your claim or start the process of filing a lawsuit today by contacting Hissey Mulderig & Friend toll-free at 1-866-806-8117, or by sending us a message using the free contact form located at the top of this page.